diabetestalk.net

Metformin Combination Products

Metformin Combination - Price List Of 139 Brands

Metformin Combination - Price List Of 139 Brands

Blood Sugar-Conversion Blood Sugar Chart Diabetes Risk Assessment Calculator Glycemic Index Calculator HbA1c or A1c Calculator for Blood Glucose View all Adult Height Potential Height and Weight for Children Attention Deficit Hyperactivity Disorder Calculator Development Milestone Immunisation View All Check Your Prostate Gland Drugs and Sexual Problem Calculator Depression Calculator Preventive Health - Screening Tests & Charts Sexual Symptoms (Undesirable) and Drugs Calculator View All Multiple Pregnancy Calculator Ovulation Calculator / Ovulation Calendar / Ovulation Chart Pregnancy Due Date Calculator Pregnancy Confirmation Calculator Virginity Calculator View All Frame Size Calculator Height and Weight for Children Height and Weight by Body Frame for Adults Ideal Baby Weight Ideal Body Weight - Adults View All Alzheimer's Risk Assessment Calculator Dementia Risk Calculator Weight Loss Calculator Adult ADHD Screening Calculator Age for Marriage License View All Heart Attack Risk Calculator Cholesterol Risk Calculator Diabetes Risk Assessment Calculator Osteoporosis Risk Chart Stroke Risk Calculator View All Daily Calorie Requirements Daily Calorie Requirement for Age and Lifestyle Recommended Intake of Minerals Vitamins and Minerals in Food Items Daily Calorie Counter for Indian Food View All Activity Calorie Calculator Blood Pressure Calculator Blood Pressure Chart Breath Calculator Cardiac Risk or Risk of Heart Attack View All Continue reading >>

U.s. Fda Approves Invokamet® Xr (canagliflozin / Metformin Hydrochloride Extended-release) For The Treatment Of Adults With Type 2 Diabetes

U.s. Fda Approves Invokamet® Xr (canagliflozin / Metformin Hydrochloride Extended-release) For The Treatment Of Adults With Type 2 Diabetes

RARITAN, N.J., Sept. 21, 2016 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved INVOKAMET® XR—a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)—for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes when treatment with the two medications is appropriate.1 INVOKAMET® XR combines INVOKANA® (canagliflozin), the most prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, with more than 9 million U.S. prescriptions since launch,2 and an XR formulation of metformin. Metformin is commonly prescribed as an initial therapy for the treatment of type 2 diabetes. "INVOKAMET® XR offers the convenience of once-daily dosing and provides physicians needed flexibility for tailoring treatment to the needs of type 2 diabetes patients, especially those with higher A1C levels," said John Anderson, M.D.,* Frist Clinic, Nashville, Tenn. "As with INVOKAMET®, physicians can prescribe the XR formulation to adults when they are first diagnosed with type 2 diabetes or as additional therapy for people whose A1C levels are not well controlled with either agent alone." Phase 3 studies have shown the combination of INVOKANA® and metformin reduces A1C significantly more than metformin alone, sitagliptin plus metformin, or glimepiride plus metformin. Treatment with INVOKANA® as an add-on to metformin also demonstrated greater reductions in the secondary endpoints of body weight and systolic blood pressure. The approved indication for INVOKAMET® XR aligns with current type 2 diabetes treatment guidelines from the American Association of Clinical Endocrinologists and American College of Continue reading >>

Fda Drug Safety Communication: Fda Revises Warnings Regarding Use Of The Diabetes Medicine Metformin In Certain Patients With Reduced Kidney Function

Fda Drug Safety Communication: Fda Revises Warnings Regarding Use Of The Diabetes Medicine Metformin In Certain Patients With Reduced Kidney Function

[ 4-8-2016 ] The U.S. Food and Drug Administration (FDA) is requiring labeling changes regarding the recommendations for metformin-containing medicines for diabetes to expand metformin’s use in certain patients with reduced kidney function. The current labeling strongly recommends against use of metformin in some patients whose kidneys do not work normally. We were asked1,2 to review numerous medical studies regarding the safety of metformin use in patients with mild to moderate impairment in kidney function,3-14 and to change the measure of kidney function in the metformin drug labeling that is used to determine whether a patient can receive metformin. We have concluded our review, and are requiring changes to the labeling of all metformin-containing medicines to reflect this new information. Health care professionals should follow the latest recommendations when prescribing metformin-containing medicines to patients with impaired kidney function. Patients should talk to their health care professionals if they have any questions or concerns about taking metformin. Metformin-containing medicines are available by prescription only and are used along with diet and exercise to lower blood sugar levels in patients with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. Metformin-containing medicines are available as single-ingredient products and also in combination with other drugs used to treat diabetes (see FDA Approved metformin-containing Medicines). The current drug labeling strongly recommends against metformin use in some patients whose kidneys do not work normally because use of metformin in these patients can increase the risk of developing a serious and potentially dead Continue reading >>

Combination Medications For Type 2 Diabetes

Combination Medications For Type 2 Diabetes

Some medications combine the effects of two medications, and that has one main advantage. Many people with type 2 diabetes end up taking multiple prescriptions anyway, so it can be convenient to have them combined in one pill. A potential drawback of using a combination medication is that it’s harder to adjust the dosage; the medications come with certain doses of one medication to the other. Examples of combination medications for type 2 diabetes: Metformin and glipizide (Metaglip) Rosiglitazone and glimepiride (Avandaryl) Pioglitazone and metformin (ACTOplus Met) Metformin and glyburide (Glucovance) Rosiglitazone and metformin (Avandamet) Pioglitazone and glimepiride (duetact) Continue reading >>

List Of Antidiabetic Combinations:

List Of Antidiabetic Combinations:

Antidiabetic combinations are medicines with two or more classes of antidiabetic agents (with different mechanisms of action) in one pill or dose. Just having one pill may improve compliance and better glycemic control. Ilumya Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of... Trogarzo Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of... Cimduo Cimduo (lamivudine and tenofovir disoproxil fumarate) is a combination of two nucleo(t)side reverse... ZTlido ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of... The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Subscribe to receive email notifications whenever new articles are published. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Feb 28th, 2018), Cerner Multum (updated Mar 15th, 2018), Wolters Kluwer (updated Mar 1st, 2018) and others. To view content sources and attributions, please refer to our editorial policy . Continue reading >>

Triple Fixed Drug Combinations In Type 2 Diabetes

Triple Fixed Drug Combinations In Type 2 Diabetes

Type 2 diabetes is characterized by progressive beta-cell failure that results in sequential adding of different oral and injectable medications to achieve optimal glycemic control.[1,2] This necessitates administration of multiple tablets or pills to achieve good glycemic control as the disease progresses.[2] In addition, subjects with type 2 diabetes may have other co-morbidities such as dyslipidemia, hypertension and cardiovascular disease, which further increase the burden of medications. Polypharmacy with increased pill burden and dosing frequency is identified as one of the factors responsible for poor adherence to oral hypoglycemic therapy.[3] Even in countries with high access to healthcare, only 39% of patients reported good medication adherence.[4] In a study of 2741 patients on oral antidiabetic drug (OAD), there was an inverse relationship between OAD adherence and HbA1c; controlling for baseline HbA1c and therapy regimen, each 10% increase in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (P = 0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the nonadherent ones.[5] Go to: One method to improve drug adherence is to use fixed drug combinations (FDC).[6] United States Food and Drugs Administration (USFDA) defines FDC as “two or more drugs may be combined in a single dosage form when each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such con-current therapy as defined in the labeling for the drug.”[7] The rationality of FDCs should be based on certain aspects such as: The drugs in the combination should act by differe Continue reading >>

Actoplus Met, Actoplus Met Xr Drug Imprint

Actoplus Met, Actoplus Met Xr Drug Imprint

(pioglitazone and metformin hydrochloride) Tablets CONGESTIVE HEART FAILURE AND LACTIC ACIDOSIS Thiazolidinediones, including pioglitazone, which is a component of ACTOPLUS MET, cause or exacerbate congestive heart failure in some patients [see WARNINGS AND PRECAUTIONS ]. After initiation of ACTOPLUS MET, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOPLUS MET must be considered [see WARNINGS AND PRECAUTIONS ]. ACTOPLUS MET is not recommended in patients with symptomatic heart failure. Initiation of ACTOPLUS MET in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS ]. Lactic acidosis is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic impairment, renal impairment, and acute congestive heart failure [see WARNINGS AND PRECAUTIONS ]. The onset is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap, and elevated blood lactate [see WARNINGS AND PRECAUTIONS ]. If acidosis is suspected, ACTOPLUS MET should be discontinued and the patient hospitalized immediately [see WARNINGS AND PRECAUTIONS ]. ACTOPLUS MET tablets are a thiazolidinediones andbiguanide combination product that contains two oral antidiabetic medications:pioglitazone hydrochlori Continue reading >>

Metformin

Metformin

Metformin may rarely cause a serious, life-threatening condition called lactic acidosis. Tell your doctor if you have kidney disease. Your doctor will probably tell you not to take metformin. Also, tell your doctor if you are over 65 years old and if you have ever had a heart attack; stroke; diabetic ketoacidosis (blood sugar that is high enough to cause severe symptoms and requires emergency medical treatment); a coma; or heart or liver disease. Taking certain other medications with metformin may increase the risk of lactic acidosis. Tell your doctor if you are taking acetazolamide (Diamox), dichlorphenamide (Keveyis), methazolamide, topiramate (Topamax, in Qsymia), or zonisamide (Zonegran). Tell your doctor if you have recently had any of the following conditions, or if you develop them during treatment: serious infection; severe diarrhea, vomiting, or fever; or if you drink much less fluid than usual for any reason. You may have to stop taking metformin until you recover. If you are having surgery, including dental surgery, or any major medical procedure, tell the doctor that you are taking metformin. Also, tell your doctor if you plan to have any x-ray procedure in which dye is injected, especially if you drink or have ever drunk large amounts of alcohol or have or have had liver disease or heart failure. You may need to stop taking metformin before the procedure and wait 48 hours to restart treatment. Your doctor will tell you exactly when you should stop taking metformin and when you should start taking it again. If you experience any of the following symptoms, stop taking metformin and call your doctor immediately: extreme tiredness, weakness, or discomfort; nausea; vomiting; stomach pain; decreased appetite; deep and rapid breathing or shortness of breath; dizzi Continue reading >>

Two-in-one: Combination Pills

Two-in-one: Combination Pills

Combination Meds What do a Swiss Army knife, Pantene Pro-V Full & Thick 2-in-1 Shampoo+Conditioner, and Glucovance have in common? They're all combination products, designed to save you time, money, or both. Drug companies are introducing more combo medications -- two drugs in one pill -- to take advantage of patent expirations and competition from generics. Glucovance is a combination of glyburide and metformin, two medications that help people with type 2 control blood glucose. Most combination pills deliver just two different types of medicine. Usually the two meds work together to treat one disease in different ways. Some pills contain two drugs to treat conditions that commonly occur together, such as high blood pressure and high cholesterol. Diabetes Combo Pills Actoplus Met: Combines Actos and metformin Avandamet: Combines Avandia and metformin Avandaryl: Combines Avandia and glimepiride Duetact: Combines Actos and glimepiride Glucovance: Combines glyburide and metformin Janumet: Combines Januvia and metformin Metaglip: Combines glipizide and metformin The Upside of Combo Pills Combination diabetes drugs can encourage people to take medications as prescribed -- and can save them money, says Shannon Miller, a professor of pharmacy practice at Albany College of Pharmacy in New York. Typically, insurance companies charge a copay for each prescription received. Combination pills require just one copay, even though you're getting two medications, she says. For Jack (last name withheld to protect privacy), who has type 2 diabetes, switching to combination drugs to control blood glucose, high blood pressure, and high cholesterol cut his number of daily pills from 11 to seven. He saves $40 a month on copays, for an annual savings of $480. Although costs vary based on spe Continue reading >>

New Metformin Fixed-dose Combinations Pbs Listed

New Metformin Fixed-dose Combinations Pbs Listed

New metformin fixed-dose combinations PBS listed New metformin fixed-dose combinations PBS listed Four new metformin/gliptin fixed-dose combinations (FDCs) for the treatment of type 2 diabetes are now available on the PBS: metformin with alogliptin (Nesina Met), which was listed on 1 February 2014 metformin XR with saxagliptin (Kombiglyze XR) and linagliptin with metformin (Trajentamet), which were both listed on 1 March 2014 metformin XR and sitagliptin (Janumet XR) listed from 1 May 2014 (Table 1). All four products are listed as Authority required (Streamlined) benefit for treatment of patients whose HbA1c is > 7% before starting a dipeptidyl peptidase 4 inhibitor (gliptin), despite treatment with metformin. It should be noted that there is no requirement in the listing restriction for patients to have trialled, or have contraindications to, sulfonylurea (Table 1). Metformin extended release versus immediate release Two of the four new combinations contain the metformin extended-release (XR) formulation. In clinical trials metformin XR has been shown to have efficacy comparable to that of immediate-release (IR) metformin. 1, 2 In addition to comparable efficacy it is claimed that the metformin XR formulation results in fewer GI side effects than metformin IR. 2-4 Metformin XR may therefore be an option for patients who experience an unacceptable level of GI side effects with metformin IR. 2, 4, 5 However, a retrospective cohort study investigating relative GI tolerability only showed a lower incidence of GI side effects for patients who had been switched from metformin IR to metformin XR after GI upset, or for treatment-nave patients who had been started on metformin XR. 6 The study did not show any difference overall in GI adverse events between groups given IR or Continue reading >>

Type 2 Diabetes: Synjardy® (empagliflozin/metformin Hydrochloride) Approved In The European Union

Type 2 Diabetes: Synjardy® (empagliflozin/metformin Hydrochloride) Approved In The European Union

Ingelheim, Germany and Indianapolis, US, 28 May, 2015 – Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance. Synjardy® combines empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), commonly prescribed for the treatment of T2D. Empagliflozin was approved in the EU in May 2014 and is available in many countries as an oral, once-daily tablet, marketed as Jardiance®.1 Synjardy® is indicated for use alongside diet and exercise to improve blood glucose control in adults with T2D when they are:2 Inadequately controlled on their maximally tolerated dose of metformin alone Inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin Already being treated with the combination of empagliflozin and metformin as separate tablets “A single medicine is often not sufficient for patients to maintain blood glucose control in the long term, resulting in the need for combinations of blood glucose-lowering drugs,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “We are delighted to offer this single-pill combination of two agents with different mechanisms. Synjardy® may help adults with T2D achieve their blood glucose targets with the added benefit of a convenient treatment regimen.” The marketing authorisation follows the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in March 2015. About the Phase III Clinical Trials2 The marketing authorisation is based o Continue reading >>

Sglt2 Inhibitor / Biguanide Combinations - Goodrx

Sglt2 Inhibitor / Biguanide Combinations - Goodrx

Drug Price Search Get the GoodRx Mobile App How GoodRx Works GoodRx Discount Card About GoodRx Browse By Health Condition Pill Identifier Find Pharmacies Near Me Latest News Help and FAQs Contact Us SGLT2 inhibitor and biguanide combinations are used to treat type 2 diabetes. The SGLT2 inhbitor removes excess glucose by blocking reabsorption through the kidneys, while the biguanide lowers blood sugar levels and decreases the amount of glucose that is absorbed. By providing your email address, you agree to receive emails containing coupons, refill reminders and promotional messages from GoodRx. You can unsubscribe anytime. Put GoodRx discounts on your home screen by downloading our top-rated mobile apps for iOS and Android for free GoodRx gathers prices and discounts from multiple sources, including published price lists, drug manufacturers, claims information and data provided to us by pharmacies. Our coupons are provided by Pharmacy Benefit Managers (PBMs), who maintain contracts with pharmacies to provide discounts. The prices we show are our best estimate; while we believe our data to be accurate, prices change frequently and we cant guarantee that the price we display will exactly match the price you receive at the pharmacy. To find your exact price, please contact the pharmacy (and note that the pharmacy will need to process the information shown on your coupon to confirm the price.)GoodRx provides no warranty for any pricing data or other information. We are not sponsored by or affiliated with any of the pharmacies identified in our price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders. All data provided is for informational purposes only and is not meant to be a substitute for professiona Continue reading >>

New Metformin Combination Medicine Approved For Type 2 Diabetes

New Metformin Combination Medicine Approved For Type 2 Diabetes

On August 27, the U.S. Food and Drug Administration (FDA) approved the combination oral diabetes medicine Synjardy for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. Synjardy, a joint development of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, combines empagliflozin (brand name Jardiance), an SGLT2 inhibitor, and metformin (brand name Glucophage and others). In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main proteins responsible for this reabsorption is SGLT2. By inhibiting the action of SGLT2, Jardiance blocks the reabsorption of glucose by the kidneys, promoting a loss of glucose in the urine and lowering blood glucose levels. Metformin works by decreasing the amount of glucose made by the liver and by improving insulin sensitivity in the liver, muscle, and fat cells. Synjardy, the third combination medicine containing empagliflozin approved in the United States, will be offered in doses of 5 milligrams of empagliflozin/500 milligrams of metformin, 5 milligrams of empagliflozin/1,000 milligrams of metformin, 12.5 milligrams of empagliflozin/500 milligrams of metformin, and 12.5 milligrams of empagliflozin/1,000 milligrams of metformin, to be taken twice daily with meals. The approval of Synjardy was based on results from multiple studies of empagliflozin and metformin alone or combined with a sulfonylurea that showed reductions in blood sugar levels compared to placebo (inactive treatment). This medicine should not be used in people with Type 1 diabetes, diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body), or severe kidney problems. As with all medicines containing metfo Continue reading >>

Description And Brand Names

Description And Brand Names

Drug information provided by: Micromedex US Brand Name Metaglip Descriptions Glipizide and Metformin combination is used to treat high blood sugar levels that are caused by a type of diabetes mellitus or sugar diabetes called type 2 diabetes. Normally, after you eat, your pancreas releases insulin to help your body store excess sugar for later use. This process occurs during normal digestion of food. In type 2 diabetes, your body does not work properly to store the excess sugar and the sugar remains in your bloodstream. Chronic high blood sugar can lead to serious health problems in the future. Proper diet is the first step in managing type 2 diabetes but often medicines are needed to help your body. With two actions, the combination of glipizide and metformin helps your body cope with high blood sugar. Glipizide stimulates the release of insulin from the pancreas, directing your body to store blood sugar. Metformin has three different actions: it slows the absorption of sugar in your small intestine; it also stops your liver from converting stored sugar into blood sugar; and it helps your body use your natural insulin more efficiently. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: Tablet Copyright © 2018 Truven Health Analytics Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes. Continue reading >>

Oral Diabetes Medications Summary Chart

Oral Diabetes Medications Summary Chart

What Oral Medications Are Available for Type 2 Diabetes? Type 2 diabetes results when the body is unable to produce the amount of insulin it needs to convert food into energy or when it is unable to use insulin appropriately. Sometimes the body is actually producing more insulin than is needed by a person to keep blood glucose in a normal range. Yet blood glucose remains high, because the body's cells are resistant to the effects of insulin. Physicians and scientists believe that type 2 diabetes is caused by many factors, including insufficient insulin and insulin resistance. They increasingly believe that the relative contribution each factor makes toward causing diabetes varies from person to person. It is important to know the name of your diabetes medicine (or medicines), how it is taken, the reasons for taking it and possible side-effects. Diabetes Pills How to Take How They Work Side Effects Of Note Biguanides Metformin (Glucophage) Metformin liquid ( Riomet) Metformin extended release (Glucophage XR, Fortamet, Glumetza) Metformin: usually taken twice a day with breakfast and evening meal. Metformin extended release: usually taken once a day in the morning. Decreases amount of glucose released from liver. Bloating, gas, diarrhea, upset stomach, loss of appetite (usually within the first few weeks of starting). Take with food to minimize symptoms. Metformin is not likely to cause low blood glucose. In rare cases, lactic acidosis may occur in people with abnormal kidney or liver function. Always tell healthcare providers that it may need to be stopped when you are having a dye study or surgical procedure. Sulfonylureas Glimepiride (Amaryl) Glyburide (Diabeta, Micronase) Glipizide (Glucotrol, Glucotrol XL) Micronized glyburide (Glynase) Take with a meal once or twice Continue reading >>

More in diabetes